# Tirzepatide: The Largest Weight Figures, and the Thinnest Partition

> Tirzepatide: Research Overview — Metabolic & Weight Research Peptides — Private Label Peptide — A review of the published tirzepatide (Mounjaro, Zepbound) literature within Metabolic & Weight research peptides: what SURMOUNT-1, SURMOUNT-5 and SURPASS-2 measured, the dual GIP/GLP-1 mechanism, and where body-composition evidence sits.

**01 / METABOLIC & WEIGHT RESEARCH**

A dual GIP/GLP-1 receptor agonist with the biggest numbers in this reference list — reported, in every trial numbered here, as body weight rather than as fat mass and lean mass.

## The short version

Tirzepatide (Mounjaro, Zepbound) is a synthetic peptide that acts on two gut-hormone receptors at once. Gut hormones called incretins are released after eating and tell the pancreas to release insulin; tirzepatide imitates two of them rather than one.

In large trials it produced the biggest average weight reductions of any compound on this desk. In a head-to-head study against semaglutide, average weight change at 72 weeks was -20.2% against -13.7% [1].

The catch, for a review about muscle, is what those trials put in their results tables. They reported total body weight, waist measurements and blood-sugar markers. They did not report how much of the lost weight was fat and how much was lean tissue. That split was examined in separate analyses that are not among the numbered sources here, and this page is explicit about which figures come from where.

## What it is

Tirzepatide is a linear 39-amino-acid synthetic peptide built on the native sequence of glucose-dependent insulinotropic polypeptide (GIP). A C20 fatty diacid — eicosanedioic acid — is attached through a glutamic acid linker and two short polyethylene-glycol-like spacer units to a lysine side chain. That fatty-acid arm binds serum albumin, which is what stretches the molecule's residence time in circulation far enough to support once-weekly administration in the trials [2].

It is classed as a dual GIP and glucagon-like peptide-1 (GLP-1) receptor agonist, and it was the first agent of that class to reach approval. Regulatory status is unusually broad for a peptide on this desk: approval came first for type 2 diabetes in May 2022, then for chronic weight management in adults with obesity or with overweight plus a weight-related condition, and subsequently for moderate-to-severe obstructive sleep apnoea in adults with obesity [2]. All approved formulations are prescription-only. The reference chapter is also explicit that weight-loss use preceded the weight-management approval as an off-label application, and that the agent is not approved for type 1 diabetes [2].

It is not, on the current World Anti-Doping Agency list, specifically prohibited as a performance-enhancing agent — a point worth stating precisely, because it is a prescription medicine and the absence of a doping prohibition is not a statement about medical or regulatory appropriateness.

## How it works

A single peptide engages two receptors. Activating the GIP receptor and the GLP-1 receptor together enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite and food intake. In the trial programme that combination produced larger glycaemic and weight effects than selective GLP-1 receptor agonism alone [5].

The pharmacology is not symmetrical, and the asymmetry has a name. Receptor-occupancy and signalling assays showed tirzepatide is an imbalanced dual agonist: it engages the GIP receptor to a greater degree than the GLP-1 receptor, and its GLP-1 receptor signalling is biased toward cyclic AMP generation over beta-arrestin recruitment, with weaker receptor internalisation than native GLP-1 produces. In primary islet experiments beta-arrestin1 limited the insulin response to GLP-1 but not to GIP or to tirzepatide [6].

The discovery paper for the molecule, then designated LY3298176, established the same profile from the other end. It activated both receptors in vitro, improved glucose-dependent insulin secretion and glucose tolerance in mice, and on chronic administration reduced body weight and food intake in mice significantly more than a selective GLP-1 receptor agonist did. A phase 1 programme of single- and multiple-ascending-dose studies in healthy subjects plus a four-week phase 1b proof-of-concept study in type 2 diabetes, 142 subjects dosed in total, supported once-weekly administration and showed reduced fasting glucose and body weight against placebo [7].

None of that mechanism is muscle-specific. The described route to weight loss runs through appetite, gastric emptying and insulin-glucagon dynamics — an intake-side mechanism. Nothing in the published mechanism proposes a signal that would preferentially protect skeletal muscle while fat is mobilised.

## What the research shows

**SURMOUNT-1.** A 72-week phase 3 double-blind randomised controlled trial in 2,539 adults with obesity — body-mass index of 30 or above, or 27 or above with a weight-related complication — and without diabetes. Once-weekly tirzepatide produced a mean weight change at week 72 of -15.0% in the 5 mg arm, -19.5% at 10 mg and -20.9% at 15 mg, against -3.1% on placebo. The most common adverse events were gastrointestinal, mostly mild to moderate, and occurred chiefly during dose escalation [4].

**SURMOUNT-5.** An open-label phase 3b head-to-head trial in 751 adults with obesity and without type 2 diabetes, randomised to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg), once weekly for 72 weeks. Least-squares mean weight change at week 72 was -20.2% with tirzepatide against -13.7% with semaglutide, a difference that reached statistical significance. Tirzepatide also produced a greater reduction in waist circumference and higher proportions of participants reaching the 10%, 15%, 20% and 25% weight-loss thresholds [1].

**SURPASS-2.** An open-label 40-week phase 3 trial in 1,879 adults with type 2 diabetes. Once-weekly tirzepatide at 5, 10 and 15 mg reduced glycated haemoglobin by an estimated 2.01, 2.24 and 2.30 percentage points respectively against 1.86 percentage points with semaglutide 1 mg, meeting noninferiority and then superiority at all three doses. Body-weight reductions were greater with tirzepatide, with treatment differences of -1.9, -3.6 and -5.5 kg. Adverse events were again predominantly gastrointestinal and mostly mild to moderate [5].

**Safety-signal meta-analysis.** A systematic review and meta-analysis of nine randomised controlled trials covering 9,871 participants examined two specific signals against controls that included basal insulin, selective GLP-1 receptor agonists and placebo. Pancreatitis was not significantly increased (relative risk 1.46, 95% confidence interval 0.59 to 3.61). The composite of gallbladder or biliary disease was significantly increased (relative risk 1.97, 95% confidence interval 1.14 to 3.42), although no individual component — cholelithiasis, cholecystitis or biliary disease — reached significance on its own [3].

The endpoint list across those four sources is worth reading as a list. Body weight in percent and in kilograms; waist circumference; proportions crossing weight thresholds; glycated haemoglobin; adverse-event rates. Fat mass and lean mass appear nowhere in it.

## Reported effects, cautions and safety

What follows in this first paragraph is anecdotal, not clinical evidence: it summarises what people describe in patient and research communities, without quantities, schedules or protocols of any kind. The most consistent reported benefit is a marked quieting of intrusive food-related thought — the running mental loop about the next meal simply fading — often accompanied by reports of increased energy as weight declines, better sleep and less snoring, easier movement and less joint discomfort, and improved mood and confidence. The most consistent reported burdens are nausea concentrated around each dose increase, an alternating pattern of constipation and loose stools attributed to slowed gastric emptying, sulfurous burping, injection-site redness and tenderness, altered taste and sudden aversion to foods previously enjoyed, hair shedding appearing some months in, and stalls in scale movement that community members describe as emotionally difficult but usually temporary. Relevant to this desk's subject, a recurring community theme is concern about losing muscle alongside fat, reported most often by people doing resistance training who notice a drop in performance or a softer physique, with discussion converging on protein intake and continued training. All of that is self-report, unverified, and not a clinical finding.

The documented cautions are a different class of statement. Gastrointestinal intolerance during dose escalation is the dominant adverse-effect profile and the main driver of discontinuation, established across the trial programme [4]. The prescribing information carries a boxed warning for thyroid C-cell tumours derived from rodent studies, and a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is treated as a contraindication; whether the rodent finding translates to humans is not established [2]. Gallbladder and biliary disease is a consistent, statistically significant signal in pooled randomised data, plausibly connected to the rate and magnitude of weight loss itself [3]. Pancreatitis is label-flagged and monitored but was not significantly increased in the same pooled analysis [3].

Beyond those, several cautions in the compound record are documented but sit outside the sources numbered on this page: the label-directed caution about hypoglycaemia when the agent is combined with insulin or a sulfonylurea; delayed gastric emptying as a periprocedural consideration around sedation and anaesthesia; reduced reliability of oral hormonal contraception during titration for the same gastric-emptying reason; volume depletion from severe gastrointestinal losses; hair shedding attributed to the speed of weight loss rather than to drug toxicity; and substantial weight regain after discontinuation, which frames the agent as a chronic rather than short-course therapy. Each of those is a matter for a prescriber, not for a reader of a literature review.

## Where it fits in the muscle-sparing question

Tirzepatide occupies the most awkward position on this desk. It has the largest, best-powered weight-loss evidence base of the four compounds reviewed here, and among the sources numbered on this site it has the least direct evidence about what tissue that weight came from.

That is not an accusation of poor trial design. SURMOUNT-1 and SURMOUNT-5 were built to answer whether and how much weight comes off, and they answered it decisively [4][1]. SURPASS-2 was built around glycaemic control and answered that [5]. Body composition was a separate scientific question, addressed by separate analyses, and it is entirely normal for a phase 3 efficacy programme to be structured that way. The consequence for a reader is nonetheless real: the figure that circulates about this compound — roughly a fifth of body weight, in 72 weeks — is a scale figure [1], and a scale figure cannot distinguish the outcome a person usually wants from the outcome they usually do not.

The compound record acknowledges the gap directly. It lists loss of lean mass alongside fat mass during rapid weight reduction as an active area of investigation, with systematic reviews assessing the magnitude of skeletal-muscle change, and it lists a narrative review proposing resistance exercise as a strategy for preserving muscle during incretin therapy. Those supporting publications are outside this site's composed reference list, so this digest does not quote their numerical estimates. The record is equally explicit that the clinical significance of lean-mass loss is still being defined, because few studies have measured objective physical function alongside tissue change.

The honest summary is short. Tirzepatide demonstrably removes a large amount of body weight. Nothing in the numbered evidence base reviewed here demonstrates that it spares muscle. The body-composition question therefore remains distinct from the weight-loss result, and any proposed preservation strategy remains a subject for research rather than advice from this review.

---

Private Label Peptide is a review of published metabolic-peptide research that keeps the instrument in view — what each study weighed, scanned or only estimated, and in which population — and it prescribes nothing, dispenses nothing and supplies nothing.